Does Rallies track congressional trades in DXCM?

Yes. Rallies tracks politician and congressional stock disclosures for DXCM, including reported purchases, sales, dates, owners, and trade amounts when available.

Is DXCM research on Rallies investment advice?

No. Rallies provides research, data, and educational context for DXCM. It does not provide personalized investment advice.

DXCM (Dexcom) Stock Analysis - Politician Trades

Dexcom (DXCM) is a publicly traded Healthcare sector company. As of May 20, 2026, DXCM trades at $71.03 with a market cap of $25.12B and a P/E ratio of 33.13. DXCM moved +6.60% today. Year to date, DXCM is +5.60%; over the trailing twelve months it is -18.20%. Its 52-week range spans $54.11 to $93.25. Analyst consensus is strong buy with an average price target of $80.10. Rallies surfaces DXCM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Which politicians traded DXCM stock?

Recent politician trading activity in DXCM includes disclosures from John Boozman, Michael McCaul, Rob Bresnahan, Michael McCaul, and Jefferson Shreve. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.

DXCM Key Metrics

Key financial metrics for DXCM
Metric	Value
Price	$71.03
Market Cap	$25.12B
P/E Ratio	33.13
EPS	$2.14
Dividend Yield	0.00%
52-Week High	$93.25
52-Week Low	$54.11
Volume	9.83M
Avg Volume	0
Revenue (TTM)	$4.66B
Net Income	$836.30M
Gross Margin	60.10%

Congressional Trades in DXCM

John Boozman purchase DXCM on Jan 26, 2026 (amount: $15.00K) for Joint.
Michael McCaul purchase DXCM on Sep 22, 2025 (amount: $15.00K) for Spouse.
Rob Bresnahan purchase DXCM on May 15, 2025 (amount: $15.00K).
Michael McCaul purchase DXCM on Apr 8, 2025 (amount: $100.00K) for Spouse.
Jefferson Shreve sale DXCM on Apr 7, 2025 (amount: $50.00K).

Latest DXCM News

Dexcom Upgraded to Buy on Forecasted Gross Margin Increase through 2026 — May 12, 2026
DexCom drops as CMS reimbursement-risk chatter revives pricing pressure fears — May 4, 2026
DexCom jumps as Q1 revenue climbs 15% and 2026 margin outlook rises — May 1, 2026
Dexcom Grows Q1 Revenue 15% to $1.2B, Keeps FY26 Outlook Unchanged — May 1, 2026
Dexcom Q1 Revenue Up 15%, Gross Margin Climbs to 63.5% — May 1, 2026

Recent DXCM Insider Trades

Heller Bridgette P sold 1.01K (~$60.73K) on May 12, 2026.
Brown Michael Jon sold 1.70K (~$107.17K) on Apr 15, 2026.
Brown Michael Jon sold 1.70K (~$110.24K) on Mar 16, 2026.

DXCM Analyst Consensus

21 analysts cover DXCM: 0 strong buy, 19 buy, 1 hold, 1 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $80.10.

Common questions about DXCM

Which politicians traded DXCM stock?: Recent politician trading activity in DXCM includes disclosures from John Boozman, Michael McCaul, Rob Bresnahan, Michael McCaul, and Jefferson Shreve. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
Does Rallies track congressional trades in DXCM?: Yes. Rallies tracks politician and congressional stock disclosures for DXCM, including reported purchases, sales, dates, owners, and trade amounts when available.
Is DXCM research on Rallies investment advice?: No. Rallies provides research, data, and educational context for DXCM. It does not provide personalized investment advice.